Literature DB >> 16129674

An activin-A/C chimera exhibits activin and myostatin antagonistic properties.

Uwe Muenster1, Craig A Harrison, Cynthia Donaldson, Wylie Vale, Wolfgang H Fischer.   

Abstract

Activins are involved in many physiological and pathological processes and, like other members of the transforming growth factor-beta superfamily, signal via type II and I receptor serine kinases. Ligand residues involved in type II receptor binding are located in the two anti-parallel beta strands of the TGF-beta proteins, also known as the fingers. Activin-A mutants able to bind ActRII but unable to bind the activin type I receptor ALK4 define ligand residues involved in ALK4 binding and could potentially act as antagonists. Therefore, a series of FLAG-tagged activin-A/C chimeras were constructed, in each of which eight residues in the wrist loop and helix region (A/C 46-53, 54-61, 62-69, and 70-78) were replaced. Additionally, a chimera was generated in which the entire wrist region (A/C 46-78) was changed from activin-A to activin-C. The chimeras were assessed for ActRII binding, activin bioactivity, as well as antagonistic properties. All five chimeras retained high affinity for mouse ActRII. Of these, only A/C 46-78 was devoid of significant activin bioactivity in an A3 Lux reporter assay in 293T cells at concentrations up to 40 nM. A/C 46-53, 54-61, 62-69, and 70-78 showed activity comparable with wild type activin-A. When tested for the ability to antagonize ligands that signal via activin type II receptors, such as activin-A and myostatin, only the A/C 46-78 chimera showed antagonism (IC(50), 1-10 nM). Additionally, A/C 46-78 decreased follicle-stimulating hormone release from the LbetaT2 cell line and rat anterior pituitary cells in primary culture in a concentration-dependent manner. These data indicate that activin residues in the wrist are involved in ALK4-mediated signaling. The activin antagonist A/C 46-78 may be useful for the study and modulation of activin-dependent processes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16129674     DOI: 10.1074/jbc.M507236200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

Review 1.  Antagonism of activin by activin chimeras.

Authors:  Uwe Muenster; Radhika Korupolu; Ratindra Rastogi; Jessica Read; Wolfgang H Fischer
Journal:  Vitam Horm       Date:  2011       Impact factor: 3.421

Review 2.  Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.

Authors:  Pasquapina Ciarmela; Md Soriful Islam; Fernando M Reis; Peter C Gray; Enrrico Bloise; Felice Petraglia; Wylie Vale; Mario Castellucci
Journal:  Hum Reprod Update       Date:  2011-07-25       Impact factor: 15.610

Review 3.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

4.  Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors.

Authors:  Oddrun Elise Olsen; Hanne Hella; Samah Elsaadi; Carsten Jacobi; Erik Martinez-Hackert; Toril Holien
Journal:  Biomolecules       Date:  2020-03-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.